| Acquisitions | Country | Date of acquisition | Net sales, SEKm¹ | Number of employees¹ | Business area |
|---|---|---|---|---|---|
| AddVision Group | Germany | April, 2021 | 700 | 190 | Medtech |
| Healthcare 21 Group | Ireland | April, 2021 | 1,700 | 450 | Medtech |
| Bio-Connect Group | Netherlands | September, 2021 | 140 | 31 | Labtech |
| Fischer Medical ApS | Denmark | November, 2021 | 60 | 12 | Medtech |
| Camanio AB | Sweden | December, 2021 | 13 | 18 | Medtech |
| MBA Incorporado S.L | Spain | January, 2022 | 670 | 285 | Medtech |
| Business from Telia Health Monitoring | Sweden | March, 2022 | 4 | 8 | Medtech |
| O'Flynn Medical Ltd | Ireland | April, 2022 | 64 | 36 | Medtech |
| BioCat GmbH | Germany | April, 2022 | 90 | 20 | Labtech |
| JK Lab Nordic AB | Sweden | July, 2022 | 24 | 6 | Labtech |
| ¹ Refers to conditions at the time of acquisition on a full-year basis. | |||||
| According to the acquisition analyses, the acquisitions carried out during financial year 2022 were as follows: | |||
|---|---|---|---|
| Fair value | |||
| Intangible non-current assets | 582 | ||
| Other non-current assets | 428 | ||
| Inventories | 274 | ||
| Other current assets | 457 | ||
| Deferred tax liability/tax asset | -133 | ||
| Other liabilities | -1,024 | ||
| Acquired net assets | 584 | ||
| Goodwill | 412 | ||
| Consideration¹ | 996 | ||
| Less: cash and cash equivalents in acquired businesses | -200 | ||
| Contingent consideration not yet paid | -21 | ||
| Effect on the Group’s cash and cash equivalents | 775 | ||
| ¹ The consideration is stated excluding acquisition expenses. | |||
| According to the acquisition analyses, the acquisitions carried out during financial year 2021 were as follows: | |||
| Fair value | of which AddVision | of which Healthcare 21 Group | |
| Intangible non-current assets | 1,967 | 821 | 890 |
| Other non-current assets | 219 | 54 | 163 |
| Inventories | 566 | 139 | 405 |
| Other current assets | 529 | 205 | 267 |
| Deferred tax liability/tax asset | -367 | -163 | -157 |
| Other liabilities | -1,256 | -275 | -923 |
| Acquired net assets | 1,658 | 781 | 645 |
| Goodwill | 3,399 | 1,234 | 2,002 |
| Consideration¹ | 5,057 | 2,015 | 2,647 |
| Less: cash and cash equivalents in acquired businesses | -140 | -67 | -47 |
| Less: Consideration paid with shares | -1,806 | -1,004 | -802 |
| Contingent consideration not yet paid | -272 | -187 | -46 |
| Effect on the Group’s cash and cash equivalents | 2,839 | 757 | 1,752 |
| ¹ The consideration is stated excluding acquisition expenses. | |||
All acquisition analyses was determined. The unspecified amounts refer to assets and equity and are not significant.
The combined consideration for the acquisitions was SEK 996 million (5,057), of which SEK 412 million (3,399) was allocated to goodwill and SEK 582 million (1,967) to other intangible assets. The consideration consists of cash payment. The transaction costs for acquisitions with a takeover date during the 2022 financial year totalled SEK 12 million (56) and are recognised in selling expenses.
The outcome of additional contingent considerations depends on the results achieved in the companies and has a set maximum level. The fair value of not yet paid contingent consideration for acquisitions made during the financial year is calculated to SEK 21 million. which is approximately 94 percent of the maximum outcome.
The values allocated to intangible assets, such as supplier relationships, were assessed at the discounted value of future cash flows. The amortisation period is determined by estimating the annual decrease in sales attributable to each asset.
Supplier relationships are generally amortised over a period of 10 years. The goodwill that arose in connection with the acquisitions is due to the fact that the Group's position in the current market for each acquisition is expected to be strengthened and to the knowledge gained in the acquired companies.
The goodwill resulting from the acquisitions is attributable to expectations that the Group's position in the market in question for each acquisition will grow stronger and to the knowledge accumulated in the companies acquired.
The combined effect of the acquisitions, on consolidated net sales was SEK 952 million (1,750), while the combined effect on EBITA was SEK 162 million (211), operating profit was SEK 114 million (73) and after-tax profit for the year was SEK 62 million (26). Had the acquisitions, been completed on 1 January 2022, their impact would have been approximately SEK 1,011 million (2,530) on consolidated net sales, SEK 174 million (309) on EBITA, about SEK 122 million (112) on operating profit, and about SEK 68 million (48) on profit after-tax.